Recent Updates
Recently added Catalysts
A Positive Sentiment

Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence

Tuesday, October 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agilent Technologies has announced its acquisition of Proscia, a leading provider of digital pathology software, in a deal valued at $240 million. The transaction includes potential additional payments based on future performance milestones. This acquisition aims to bolster Agilent's offerings in AI-enabled digital pathology and scientific intelligence.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agilent is expanding its capabilities in digital pathology.
  • The acquisition enhances Agilent's AI-enabled scientific intelligence.
  • Proscia's software is well-regarded in the clinical and life sciences sectors.

Full Press Release Details

SANTA CLARA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Proscia®, a provider of digital pathology software for clinical and life-sciences customers, in an all-cash transaction valued at $240 million in cash at closing and up to an additional $30 million based on achieving future performance milestones. Proscia is a leading independent provider of enterprise digital pathology software, serving

Frequently Asked Questions

What is the value of Agilent's acquisition of Proscia?

The acquisition is valued at $240 million in cash, with potential additional payments.

What does Proscia provide?

Proscia is a provider of digital pathology software for clinical and life sciences.

How will this acquisition benefit Agilent?

It will enhance Agilent's capabilities in AI-enabled digital pathology and scientific intelligence.

Is the acquisition contingent on performance milestones?

Yes, there is an additional $30 million based on achieving future performance milestones.

ShareAdd on Google
Tags: A Agilent Proscia digital pathology AI acquisition
Last updated: Oct 13, 2026

Biotech snapshot

Cash runway
$1758M liquidity · $0M/mo burn
Low dilution risk